CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

Ann Neurol. 2005 Jul;58(1):151-5. doi: 10.1002/ana.20523.

Abstract

We tested the efficacy and safety of glutamine (0.6 gm/kg/day) and creatine (5 gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, double-blind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Child
  • Child, Preschool
  • Creatine / therapeutic use*
  • Glutamine / therapeutic use*
  • Humans
  • Male
  • Muscle, Skeletal / drug effects*
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Respiratory Function Tests

Substances

  • Glutamine
  • Creatine